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Abstract 
Ghrelin and Peptide YY (PYY) are two important gut hormones involved in the 
regulation of food intake and energy homeostasis. Recently, data mainly from in vitro and 
animal models have suggested that these hormones may play a role in the regulation of 
glucose homeostasis and bone density. However, previous human studies were performed 
on a small sample size, and their results are inconclusive. Moreover, important 
confounding factors were not controlled in these studies. 
In the first project, I addressed the association of circulating ghrelin with insulin 
resistance. A total of 2082 subjects from the Complex Diseases in the Newfoundland 
population: Environment and Genetics (CODING) study, participated in this 
investigation. Partial correlation analyses revealed that circulating ghrelin had significant 
inverse associations with insulin level and insulin resistance indices in the entire cohort 
(insulin: r = -0.09, p < 0.001 ; HOMA-IR: r = -0.08, p < 0.001 ; HOMA-P: r = -0.1 , p < 
0.001 ; and QUICKI: r = 0.08, p < 0.001) and also in men and women separately. These 
correlations were independent of age, percentage of trunk fat, and HDL-cholesterol. 
In the second project, I investigated the relationship between ci rculating ghrelin and PYY 
and bone density using the same cohort, by controlling major confounding factors: age, 
BMI, physical activity, alcohol consumption, and smoking. A total of 2257 adult subjects 
were recruited in this study. Our results suggest a beneficial effect of circulating ghrel in 
level on bone density indices (L2-L4 BMD, L2-L4 Z-score, femoral neck BMD, femoral 
neck Z-score, total hip BMD, and total hip Z-score) in women. This effect was 
independent of the major confounding factors. However, we did not find evidence that 
PYY is significantly associated with the bone density parameters. 
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Ghrelin was first discovered as a hormone that can stimulate growth hormone secretion. It 
has since been recognized that ghrelin has significant effects on appetite and energy 
homeostasis. The name "ghrelin" comes from the root "ghre", which is a Proto-Indo-
European word for "grow" [1]. Human ghrelin can be purified from the stomach after 
several steps for gel filtration, two-ion exchange high performance liquid chromatography 
(HPLC), ghrelin-specific radioimmunoassay (RIA), intracellular calcium influx assays, 
and purification using C 18 HPLC [2]. 
Structure of ghrelin 
The human ghrelin gene is on chromosome 3p25-26. This gene is composed of 5 exons, 
and ghrelin is encoded from exons 1 and 2 [3]. Ghrelin is produced as a preprohormone 
that will change to a 28 amino acid peptide. A unique feature of ghrelin is a fatty acid 
chain modification in which the n-octanoic acid residue is bound to the serine residue at 
position three. This modification changes ghrelin to an active form, acylated ghrelin 
(Figure 1.1) [3, 4]. 
Secretion of ghrelin 
Most of the body's ghrelin is secreted from the stomach. Lower amounts are secreted in 
the pancreas, pituitary, kidney, and placenta. A limited region of the arcuate nucleus of 
the hypothalamus contains small amounts of ghrelin [5]. 
Ghrelin is mostly found in the gastric fundus. In this region, oxyntic glands in distinctive 
endocrine cells known as P/Dl cells produce ghrelin [6]. There are two types of ghrelin-
secreting cells. The first type secretes ghrelin to the lumen of the stomach where it is 
exposed to stomach contents. The second type lies near the capillary network of the 
lamina propria and secretes ghrelin to the blood [7]. 
Physiological actions of ghrelin 
Hypothalamic-pituitary actions: Intravenous injection of ghrelin stimulates growth 
hormone release both in rats and humans [1 , 8]. Moreover, ghrelin has stimulatory effects 
on the secretion of adrenocorticotropic hormone (ACTH) and prolactin [9]. Excessive 
secretion of ACTH under pathologic conditions such as Cushing disease causes weight 
gain and truncal obesity [10]. High level of circulating prolactin can also lead to 
metabolic abnormalities associated with obesity and insulin resistance [11]. 
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Figure 1.1- Structure of ghrelin [3] 
Figure 1.2- The role of PYY in the ileal brake [32] 
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Effects on food intake: Injection of ghrelin into the cerebral ventricles of rats increases 
appetite, stimulates food intake, and induces a positive energy balance that can cause 
weight gain [5]. Rapid increase of ghrelin before each meal and decrease of ghrelin after 
each meal indicate the effect of ghrelin on meal initiation. Interestingly, unlike other 
orexigenic hormones such as Neuropeptide Y (NPY), which acts only when injected to 
the brain, administration of ghrelin both peripherally and to the central nervous system 
causes the orexigenic effects [12]. 
Adiposity: Ghrelin secretion is up-regulated under conditions of negative energy balance 
such as anorexia nervosa [13]. The effect of positive energy balance on ghrelin is not 
clear. Some cross sectional studies reported decreased level of ghrelin in obese subjects 
compared with lean individuals [13, 14]. In our CODING (Complex Disease in the 
Newfoundland population: Environment and Genetics) study we did not see any 
significant difference in ghrelin concentration between various adiposity groups. 
However, in the overfeeding study, short term positive energy challenge caused a 
significant increase in the circulating ghrelin concentration [ 15]. 
Neuropeptide Y secretion: Central administration of ghrelin increases neuropeptide Y 
(NPY) and agouti-related protein (AGRP) mRNA expression in the arcuate nucleus ofthe 
hypothalamus [16]. Both NPY and AGRP are orexigenic hormones. NPY is a 36 amino 
acid peptide widely acts as a neurotransmitter [ 17]. It plays an important role in the 
regulation of body weight and energy homeostasis by increasing food intake [ 18], and 
accumulation of white fat storage and decreasing the brown fat thermogenesis [19, 20]. 
AGRP is a 132 amino acid neuropeptide which is co-expressed by NPY in the arcuate 
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nucleus of hypothalamus. Overexpression of AGRP increases the food intake, decreases 
the energy expenditure, and as a result it causes weight gain [21 , 22]. 
Effect of ghrelin on gastric motility: Ghrelin stimulates phase III-like contractions in the 
antrum and duodenum and increases gastric motility. Experimental animal studies 
showed that ghrelin can even increase the gastric motility in animals that have ileus 
because of vagotomy or post gastrointestinal operation. Therefore, the effect of ghrelin on 
gastric motility is mediated by both vagal and nonvagal pathways [23-25]. 
Effect of ghrelin on immune function: Ghrelin ' s receptors are present on human T cells 
and monocytes, and ghrelin may function as anti-inflammatory hormone [26, 27]. 
Peptide YY 
Peptide YY (PYY) is a member ofthe NPY family ofpeptides. It is released mainly from 
enteroendocrine L-cells that are more abundant in the distal part of the gastrointestinal 
tract. Enteric neurons of the stomach and pancreatic endocrine cells can also secrete small 
amount of this hormone [28]. 
Structure of PYY 
PYY is a 36 amino acid peptide with a tyrosin residue at both C and N terminal. There are 
two forms ofPYY. The form that was originally isolated from the gut has 36 amino acids 
(PYYI -36). However, PYY can also be found in the shortened form that does not have 
the first two amino acids (PYY3-36). Most of the circulating PYY is in the form of PYY 
3-36 [29]. 
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Receptors of PYY 
The NPY family of peptides has several receptor subtypes. These receptors are called Y 
receptors and all are G protein-coupled receptors. Currently, five functional Y receptors 
have been identified [30]. PYYl-36 binds to Yl, Y2 and Y5 receptors. However, 
truncated PYY (PYY3-36) mostly binds to the Y2 receptor [31]. 
Physiologic actions of PYY 
PYY inhibits gastric acid secretion. Moreover, it can slow down gastric emptying, 
motility, and delivery of food to the intestine. This action of PYY is called the "ileal 
brake" (Figure 1.2) [32]. PYY is an important hormone in the regulation of food intake 
and energy homeostasis. Most of the previous studies have shown that PYY has anorectic 
effects. pyy-l- mice are hyperphagic, and they show a significant increase in body 
weight and adiposity on a regular chow diet [33]. Moreover, peripheral infusion of PYY 
in rodents, and obese humans, inhibits food intake [34, 35]. 
Metabolic syndrome 
Metabolic syndrome has become one of the important public health challenges 
worldwide. Metabolic syndrome is the result of the co-occurrence of interrelated risk 
factors of metabolic origin mainly because of obesity and the consequent insulin 
resistance that appears. Metabolic syndrome directly promotes the development of 
atherosclerotic cardiovascular disease and increases risk for developing type 2 diabetes 
mellitus [36]. 
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Definition of metabolic syndrome 
There are several definitions for metabolic syndrome. Although there might be some 
differences between them, the commonality between all is the presence of obesity or 
insulin resistance. Table 1.1 shows different methods used to define metabolic syndrome. 
Table 1.1 -Definitions of the metabolic syndrome 
Method 
National Cholesterol 




Wildman et a/.[39] 
Definition 
presence of any three of the following five traits: 
• Abdominal obesity [waist circumference in men 2: 1 02 em 
(40 in) and in women 2:88 em (35 in)] 
• Serum triglycerides 2: 1.7 mmoi/L 
• Serum HDL cholesterol <1 mmoi/Lin men and <1.3 
mmoi/L in women 
• Blood pressure 2:130/85 mmHg 
• Fasting plasma glucose 2:5.6 mmoi/L or drug treatment 
Increased waist circumference plus any of two of the 
following: 
• Triglycerides > 1.7 mmoi/L 
• HDL cholesterol < 1.03 mmoi/L in men or <1.29 mmol/L 
in women 
• Blood pressure > 130/85 
• Fasting plasma glucose > 5.6 mmoi/L 
Two or more criteria: 
• Blood Pressure 2': 130/85 mm Hg or antihypertensive 
medication use 
• Triglyceride level 2': 150 mg/dL 
• HDL-C <1.03 mmoi/L in men or < 1.29 mmoi/L in women 
• Fasting glucose level 2': 5.6 mmoi/L 
• Insulin resistance (HOMA-IR > 5.13) [ie. The 90th 
percentile] 
• hsCRP level > 0.1 mg/L[ie. T he 90th percentile] 
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Underlying causes of metabolic syndrome 
The cause of metabolic syndrome is still unclear. Insulin resistance, which is a hallmark 
of obesity, is one of the important factors involved in pathogenesis of metabolic 
syndrome [40]. Several metabolic pathways are involved in the link between insulin 
resistance and hyperinsulinemia to metabolic risk factors. Glucose transporter 4 
(GLUT4), the key protein for transporting glucose into the cells, is regulated by insulin 
level. Insulin resistance can also affect enzymes that are involved in gluconeogenesis and 
causes the increase in endogenous glucose production [41 , 42]. Moreover, insulin 
resistance state leads to the dysregulation of chylomicron release from the gut and 
production of very low density lipoproteins (VLDLs). As a result, increase in triglyceride 
and decrease in the HDL level are observed. Detrimental effect of insulin resistance on 
cardiovascular function might be due to discrepancy between nitric oxide production and 
secretion of endothelin-1. This imbalance causes vasoconstriction, impaired blood flow, 
and increase risk for cardiovascular diseases [43). 
Previous studies on twins revealed that both genetic and environmental factors such as 
physical activity, dietary habits, age, medication use, and alcohol intake are involved in 
the pathogenesis of metabolic syndrome [ 44-46]. 
Definition and quantification of insulin resistance 
Insulin resistance is a state in which there is subnormal ~ cell function and insulin 
secretion. This dysfunction leads to postprandial hyperglycemia, and consequently, an 
exaggerated insulin response that down regulates insulin receptors. Chronic consequences 
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of insulin resistance include the development of type 2 diabetes, cardiovascular disease, 
and other malignancies associated with obesity [44]. 
The euglycemic hyperinsulinemic clamp technique is the gold standard for the 
measurement of insulin resistance [47]. In this method, two catheters are inserted in the 
veins and plasma insulin concentration is increased acutely to 100 f.!U/L and is kept at the 
same level by continuous infusion of insulin. The glucose concentration is measured once 
the insulin infusion starts, and it is maintained at 90 mg/dl by a variable infusion of 20% 
glucose. After this steady state is reached, the infusion of glucose reflects the uptake of 
glucose by the tissues and therefore it is an index for insulin sensitivity [ 48]. 
Since the euglycemic clamp is an invasive method, scientists created equations based on 
the fasting levels of insulin and glucose that can be used for the measurement of insulin 
sensitivity. Previous studies have shown that there is a good correlation between these 
equations and the results of the euglycemic clamp. The equations are mentioned in Table 
1.2 [49, 50]. 
Table 1.2- Equations used for measurement of insulin resistance 
Name Equation 
Homeostasis Model HOMA-IR = Fasting Insulin [mU/L] x Fasting Glucose [mmol/L] I 









HOMA-[3 = 20 x Fasting Insulin [mUlL]/ Fasting Glucose 
[mmol/L]-3 .5 
QUICKI = 1 I (log Fasting Insulin + log Fasting Glucose) 
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As mentioned previously, the two important appetite regulatory gut hormones, ghrelin 
and PYY, are involved in regulation of energy homeostasis and adiposity. Therefore, 
investigating the role of these hormones in the development of insulin resistance may 
provide valuable insight into underlying mechanisms responsible for the metabolic 
syndrome. 
Effect of ghrelin on insulin resistance 
Initial animal and human studies revealed that ghrelin inhibits insulin secretion and 
stimulates glucagon secretion from pancreatic islets, and infusion of exogenous ghrelin 
decreases glucose stimulated insulin secretion [51-54]. Ghrelin knockout mice showed 
improvement in insulin sensitivity and glucose homeostasis [55]. However, other studies 
do not support the proposed effect that ghrelin can have in the development of diabetes 
[56-58]. An important factor is that most studies are done on animals or small group of 
humans and they have not adequately controlled for percentage of body fat or other 
confounding factors for insulin resistance in their analyses. 
Effect of PYY on insulin resistance 
Animal investigations have shown that PYY is also involved in the regulation of glucose 
homeostasis. Studies on rodents revealed that PYY inhibits glucose stimulated insulin 
secretion from pancreatic islets [59]. Moreover, PYY knockout mice had significantly 
higher fasting or glucose-stimulated serum insulin concentrations compared to wild-types 
[60]. However, some studies revealed that PYY infusion can decrease body weight, 
improve insulin sensitivity and glucose concentration, and therefore its effect on 
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decreasing insulin level is secondary to reducing food intake and body weight [61 , 62]. 
Although there are some animal studies examining the effect of PYY on insulin 
resistance, there is still a lack of population based studies, specifically the large ones with 
the measurement of body composition for controlling adiposity in the analysis. 
Osteoporosis Definition 
Osteoporosis is one of the most common metabolic bone diseases worldwide. National 
Institute of Health consensus defined osteoporosis as a "disease characterized by low 
bone mass and micro architectural deterioration of bone tissue, leading to enhanced bone 
fragility and a consequent increase in fracture risk" [63]. According to the World Health 
Organization, osteoporosis is defined as a bone mineral density value more than 2.5 
standard deviations below the mean for the normal young Caucasian. 
Prevalence of osteoporosis 
It is estimated that approximately 44 million Americans have low bone mass, and 10 
million of this population have osteoporosis. For the women and men at the age of 50 
years, the approximate likelihood of osteoporotic fractures in their remaining life is 50% 
and 25-30% respectively. The annual cost for treating osteoporosis is 17.9 billion dollars 
and it will increase to three times more than that in 2040 [64]. 
In Canada, almost 1 in 3 women and 1 in 5 men will experience an osteoporotic fracture 
during their lifetime [65]. The annual cost of osteoporotic fractures is 2.3 - 4.1 billion 
dollars, 1.3% of Canadian health care budget. The number of hospitalizations as a result 
of osteoporosis in Canada is more than the number for stroke or heart attack. Therefore, 
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early diagnosis and understanding of the potential factors that cause osteoporosis, and the 
prevention of osteoporotic fractures, are of great value [ 66]. 
Osteoporosis diagnosis and bone density measurement 
Osteoporosis is a silent disease, which was previously diagnosed only after fracture 
occurred [67]. Due to the increasing prevalence of osteoporosis, there is a huge demand 
for the development of facilities that can help the early diagnosis of osteoporosis. 
Measurement of bone mineral density (BMD) is the best means for the prediction of 
osteoporosis. For each standard deviation decrease in BMD, there is a two fold increase in 
fracture risk. Currently, dual energy X-ray absorptiometry (DXA) of the lumbar spine and 
proximal femur is the gold standard for bone density measurement. The DXA system 
consists of a padded table that patient lies on, a movable C-arm with an X-ray tube below 
the patient that produces two different energy levels, and a detector above the patient. In 
this technique, penetration of two X-ray sources through soft tissue and bone are 
compared, and with subtraction of soft tissue, an estimate of skeletal BMD is measured. 
Radiation exposure to the patient in DXA technology is almost 3-4 mrem/site. 
Background radiation is approximately 300 mrem/year. Therefore, the radiation acquired 
through DXA is negligible [68]. 
The DXA system also gives us the values forT and Z scores. The T score values that are 
used for the diagnosis of osteoporosis compares the patient' s bone mineral density with 
the mean bone density in young adult white population. Z-score is used to compare the 
patient's BMD to a population of peers of the same ethnicity and sex [69]. 
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Pathogenesis of osteoporosis 
Age and estrogen deficiency 
Osteoporosis is the consequence of imbalanced bone remodeling. In a normal situation, 
there is a balance between bone resorption, in which osteoclasts resorb bone by 
acidification and proteolytic digestion, and bone formation, in which osteoblasts secrete 
osteoid into the osteoid cavity. Most cases of osteoporosis are primary osteoporosis, 
which are idiopathic, and result from cellular and molecular mechanisms related to 
estrogen deficiency or aging. Although primary osteoporosis can be seen in both sexes, 
the prevalence in women is two to three times more than men. The reason is that in 
women there are two stages of decrease of bone density: I) the rapid stage after 
menopause that continues for 4 to 8 years, and causes 5 to 10 percent of cortical bone loss 
and 20 to 30 percent of trabecular bone loss, and 2) the slow continuous stage that 
continues throughout the life and causes 20 to 25 percent of cortical and trabecular bone 
loss in both sexes. However, men undergo only the slow continuous stage. Therefore, 
women lose more bone compared to men [70]. 
Cellular and molecular mechanisms 
Cellular and molecular mechanisms are also involved in the pathogenesis of osteoporosis. 
For example, decrease in the estrogen level after menopause results in an increase in 
cytokines like receptor activator of nuclear factor-KB ligand (RANKL), and decrease in 
osteoprotegerin (OPG) that accelerates bone resorption, breakdown of collagen and 
matrix, and an inability of osteoblasts to compensate that [71 , 72] . 
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In spite of the higher prevalence for primary causes of osteoporosis, understanding the 
potential factors that can cause secondary osteoporosis is of great importance. Some of 
the secondary causes of osteoporosis are summarized in Table 1.3. However, there are 
still more factors that can affect bone density which have not been fully discovered and 
evaluated in human studies. Previous studies have shown that pathological conditions 
such as subtotal gastrectomy that affect the gut peptide levels can cause secondary 
osteoporosis [73]. Nevertheless, the effect of gut hormones on bone density in general 
population is still largely unknown. 
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Effect of ghrelin on bone density 
Ghrelin has been shown to increase growth hormone secretion and regulate body weight 
and energy homeostasis; however, there has been debate as to whether circulating ghrelin 
level is correlated with bone mineral density. Moreover, it is not clear whether any 
possible correlations with bone mineral density in small studies with limited statistical 
power, are true direct correlations or secondary to the direct effect of ghrelin on body 
weight and growth hormone secretion. 
In vivo and animal studies have shown that osteoblasts express ghrelin receptor and 
ghrelin increases osteoblasts proliferation and differentiation. To assess whether this 
effect is dependent on growth hormone axis, previous studies have examined the effect of 
ghrelin administration on GH deficient rats. It was discovered that even in the GH-
deficiency state, ghrelin could increase bone density. Also, in vivo studies on animals 
using concentrations of ghrelin that did not change the body weight and food intake, 
showed that the effect of ghrelin on bone density is independent of body weight [75]. 
Human studies related to the effect of ghrelin on bone density are limited and the results 
are inconsistent. Some studies reported a positive correlation between ghrelin and BMD 
[76, 77]. However, other studies have noted no correlation at all [78-80). 
Effect of PYY on bone density 
PYY can influence the regulation of body weight and energy homeostasis. Body weight 
is a key factor in determining bone density. Previous studies have shown that 
hypothalamic Y2 receptors regulate bone formation and PYY may affect bone density 
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directly through this receptor as well [81]. The initial investigations regarding the effect 
of PYY on bone density were conducted on rodents but the results were inconsistent. Y2 
receptor deficient mice had increased trabecular bone volume. However, PYY deficient 
mice had a decrease oftrabecular bone mass and developed osteopenia [81 , 82]. Very few 
cross sectional studies have been performed in humans. All ofthe studies available in the 
literature were conducted on small sample size and on metabolic conditions that affect 
PYY such as anorexia nervosa, or in athletic subjects [83, 84]. No study has been 
performed in the general population. Therefore, there is a necessity to explore the 
association of circulating ghrelin and PYY concentration and bone mineral density, with 
considering major confounding factors in a large population. 
In conclusion, insulin resistance and osteoporosis are both complex diseases with high 
prevalence, morbidity, and mortality. Therefore, understanding the factors that can be 
involved in the pathogenesis of these diseases is of critical importance. The findings from 
previous in vitro and animal studies indicate that gut hormones might be involved in the 
regulation of blood glucose and bone density. The gut produces more than 20 hormones 
with different functions. However, ghrelin and PYY were selected for this project based 
on their physiological function, anatomical location, previous evidence that suggested 
they might be linked to diabetes and osteoporosis, and more importantly lack of 
population based association studies related to the effect of these hormones on insulin 
resistance or bone density. Therefore, the objectives ofthis project are: 1) To investigate 
the association between circulating fasting ghrelin and insulin resistance adjusting for 
age, gender, percentage of body fat, and HDL- cholesterol in the general population ofthe 
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Canadian province of Newfoundland and Labrador. 2) To examine the effect of fasting 
circulating ghrelin and PYY on bone density in the general population, taking into 
consideration age, BMI, physical activity, smoking, and alcohol consumption as the most 
important confounding factors for bone density. 
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Serum acylated ghrelin is negatively correlated with the insulin 
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Abstract 
Objective: Ghrelin is a 28-amino acid orexigenic peptide synthesized mainly in the 
stomach. Acute administration of ghrelin has been found to decrease insulin secretion. 
However, little data is available regarding whether ghrelin contributes to the long-term 
regulation of insulin resistance at the population level. The aim of this study is to 
investigate the association between circulating ghrelin and insulin resistance in a large 
population based study. 
Design: A total of 2082 CODING study (Complex Diseases in the Newfoundland 
population: Environment and Genetics) subjects were assessed. Subjects were of at least 
third generation Newfoundland descent, between the ages of 20 and 79 years, and had no 
serious metabolic, cardiovascular, or endocrine diseases. Ghrelin was measured with an 
Enzyme Immunoassay method. Insulin and fasting glucose were measured by Immulite 
2500 autoanalyzer and Lx20 clinical chemistry analyzer, respectively. Homeostatic 
Model Assessment of 13 cell function (HOMA-13) and Insulin Resistance (HOMA-IR) and 
Quantitative Insulin-sensitivity Check Index (QUICK!) were used for measurement of 
insulin resistance. 
Results: Partial correlation analyses showed a significant negative correlation between 
circulating ghrelin and insulin level and insulin resistance in the entire cohort and also in 
men and women separately. The aforementioned correlation was independent of age, 
percentage of trunk fat and HDL-cholesterol. According to menopausal status, only pre-
menopausal women revealed negative correlations. 
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Conclusion: Our results suggest that except for postmenopausal women, high circulating 
ghrelin level is associated with lower insulin resistance in the general population. 
Introduction 
Diabetes mellitus is one of the most common chronic diseases worldwide. The estimated 
number of diabetic patients in 2010 was 366 million globally and it is predicted that this 
number will increase to 552 million by 2030 [1]. Type 2 diabetes is the most common 
type of diabetes. As a complex disease, both genetic and environmental factors are 
involved in development of this disease [2]. Pathogenesis of type 2 diabetes is 
complicated by several factors and insulin resistance, insulin deficiency, or both may 
contribute to this disease [3]. 
The gastrointestinal tract (gut) is the largest endocrine organ of the body. The gut 
produces hormones that have important roles in controlling body weight and energy 
homeostasis through the gut-brain axis [ 4, 5]. Previous studies showed that gastric bypass 
surgery results in a significant improvement of type 2 diabetes, and gut hormones play a 
role in this remission [6]. 
Ghrelin is a 28 amino acid orexigenic peptide synthesized mainly in stomach [7]. 
Circulating levels increase during fasting and decrease rapidly after a meal, so ghrelin has 
a role in acute changes in energy balance and satiety [8]. Ghrelin is a pleiotropic hormone 
that can influence different metabolic functions such as increasing food intake, inducing 
positive energy balance, promoting enlargement of adipocytes and also releasing growth 
hormone [9, 10]. Function of ghrelin on energy metabolism has been thought to be 
mediated by the central mechanisms, such as activation of the ghrelin receptor in the 
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hypothalamic neuropeptide Y and agouti-related protein (NPY/AgRP) neurons [11]. 
Recently accumulating data suggest that ghrelin has central and peripheral effects on 
glucose regulation and insulin level [12, 13]. 
In rats ghrelin inhibits insulin secretion and stimulates glucagon secretion from pancreatic 
islets [14]. Infusion of exogenous ghrelin in healthy humans decreases glucose stimulated 
insulin secretion [12, 15, 16]. Moreover, it was shown that fasting ghrelin in type 2 
diabetic patients is lower than in those who do not have diabetes [ 17]. Adolescent obese 
polycystic ovarian syndrome (which is characterized by insulin resistance) patients had 
lower ghrelin level compared with lean subjects and ghrelin was negatively correlated 
with Homeostatic Model Assessment oflnsulin Resistance (HOMA-IR) [18]. 
On the other hand, no association was found between insulin sensitivity measured with 
euglycemic hyperinsulinemic clamp and ghrelin level in men [19]. In a prospective 
follow up study no significant difference was found between the ghrelin levels of subjects 
who had normal glucose tolerance and those who developed impaired fasting glucose, 
impaired glucose tolerance and type 2 diabetes mellitus [20]. 
Due to the controversy of the data regarding the effect of ghrelin on insulin resistance we 
designed the present study to investigate the association between ghrelin and insulin 
resistance in a large population based study: the CODING study (The Complex Diseases 




A total of 2082 subjects (1582 women and 500 men) were enrolled from the ongoing 
nutrigenomics CODING study [21]. Volunteers were 1) between the ages of 20 and 79 
years old; 2) of at least third generation Newfoundland descent 3) without any serious 
metabolic, cardiovascular, or endocrine diseases and 4) females were not pregnant at the 
time ofthe study. 
Serum Measurement 
Venous blood samples were drawn from all volunteers following a 12 hour fasting period. 
Blood was collected into tubes with EDTA for plasma preparation and serum separator 
tubes (SST) with clot activator. SST tubes were centrifuged at 3500 rpm for 10 min and 
EDTA tubes were centrifuged at 1300g for 15 min to separate serum and plasma 
respectively. Plasma and serum samples were stored in a -80 oc freezer. 
Serum ghrelin was measured with an enzyme immunoassay method (Human Acylated 
Ghrelin Enzyme Immunoassay Kit of Spibio-bertin pharma) with the specifity of I 00 % , 
intra-assay coefficient of variation (CV) of 5. 7 % and inter-assay CV of 17 %. Insulin and 
fasting glucose were measured by Immulite 2500 immunoassay analyzer and Lx20 
clinical chemistry analyzer (Beckman Coulter lnc.CA, USA) respectively. 
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Insulin resistance measurement 
Although euglycemic hyperinsulinemic clamp is considered as the gold standard for 
measurement of insulin resistance, previous studies have shown that there is a high 
correlation between insulin resistance measured with HOMA and QUICK! and one that is 
measured by euglycemic clamp (R = 0.88, p < 0.0001 and r = 0.69, p < 0.05) [22, 23]. 
Homeostatic Model Assessment of 13-cell function (HOMA-13) and Insulin resistance 
(HOMA-IR) were calculated from fasting glucose and insulin levels using the equations 
[22] : 
HOMA-~=20xfasting insulin[mU/L] /(fasting glucose [mmol/L]-3.5) 
HOMA-IR=(fasting insulin[mU/L]xfasting glucose [mmol /L])/22.5 
Three volunteers excluded from the study because of having fasting glucose lower than 
3.5 mmol/L that result in negative values for HOMA-13. 
Quantitative insulin-sensitivity check index (QUICK!) was the other insulin sensitivity 
index that was used for measurement of insulin sensitivity. It is determined by this 
mathematical equation [24]: 
QUICKI=ll[log fasting insulin(mU/L)+log (fasting plasma glucose(mmol/L)x 18.0182)] 
Subjects were divided into diabetic and non-diabetic groups (based on the history and 
glucose level). According to the 2006 WHO criteria fasting glucose 7.0 mmol/L was 
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considered as diabetes [25]. 80 volunteers were in diabetic group and 2002 volunteers 
were in non-diabetic group. 
Anthropometric and body composition measurements 
Anthropometric measurements were taken with participants dressed in light clothing and 
without shoes. Standing height was measured to the nearest 0.1 em using a stadiometer. 
Body weight was measured to the nearest 0.1 kg using a calibrated balance scale (Health 
0 Meter, Bridgeview, IL). BMI was calculated from weight and height in kilograms per 
square meter. Waist circumference was measured midway between the lowest rib and 
iliac crest and hip circumference was measured at the widest point over the greater 
trochanters using a flexible tape measure and they were taken to the nearest millimeter. 
Dual-energy X-Ray absorptiometry (DXA) Lunar Prodigy (GE Medical Systems, 
Madison, WI) was used for measurement of body composition. 
Medication use and menopausal status 
Volunteers were divided to medication users and non-medication users. Medication users 
were those who reported using prescribed medications or multivitamins regularly. 
All of the female volunteers filled out a menstrual cycle and menopausal status 




SPSS version 18.0 was used for all of the statistical analyses. The summary statistics for 
continuous variables with normal distribution were expressed as mean and standard 
deviation. Non-normally distributed variables were expressed as median, minimum and 
maximum. The level of statistical significance was set at P value < 0.05. Logarithmic 
transformation was used for the variables that did not have normal distribution (ghrelin, 
insulin, HOMA-IR, HOMA-(3, QUICK! and Triglyceride). Analysis was performed on 
the entire cohort and also on men and women separately. Women were also divided into 
pre-menopausal and post-menopausal groups and the analysis was conducted within these 
two groups. Pearson correlation analyses were used to examine the relationship between 
various potential factors that may have an effect on ghrel in or insulin sensitivity. Partial 
correlation analyses (controlling for age, percentage of trunk fat and HDL-cholesterol) 
were also performed. General linear model (multivariative analyses) was used to compare 
insulin resistance among the ghrelin groups, in which ghrelin groups were set by ghrelin 
tertiles and the covariates were age, trunk fat percentage and HDL-cholesterol. All 
analyses were repeated excluding diabetic patients for controlling the effect of blood 
glucose. 
Ethical Considerations 
The current study was approved by the Human Investigation Committee of the Faculty of 
Medicine of Memorial University, St. John ' s, Newfoundland and Labrador, Canada and 
all of the volunteers signed informed consent to participate in the study. 
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Results 
Physical and biochemical parameters 
Mean and standard deviation of the parameters that were normally distributed are 
summarized in Table 2.1 . Ghrelin, insulin, HOMA-IR, HOMA-13, QUICK! and 
Triglyceride were not normally distributed. Median and range of these values are shown 
in Table 2.2. 
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3.18 (0.9) 
Table 2.2- Biochemical characteristics of data not normally distributed 
Variables Entire Cohort 
Median Min-Max Median 
Ghrelin (ng!L) 194.05 0.74-2339.95 193.44 
Insulin (pmoi/L) 55.90 14.40-272 55.55 
HOMA-IR 1 1.78 0.41-16.01 1.77 
HOMA-J32 109.11 12.96-3801.3 111.16 
QUICKI3 0.35 0.26-0.45 0.35 
Triglyceride 
~mmoi/L) 1.01 0.23-5.88 0.98 
HOMA-IR: Homeostatic Model Assessment oflnsulin Resistance 
2HOMA-P: Homeostatic Model Assessment of p cell function 


















Association between circulating ghrelin level and insulin resistance 
Partial correlation analyses after controlling for confounding factors (age, percentage of 
trunk fat and HDL-cholesterol) showed negative correlation between circulating ghrelin 
level and insulin, HOMA-IR, HOMA-P and positive correlation between circulating 
ghrelin level and QUICKI. This association was not gender specific and it was reported in 
both male and female subjects (Table 2.3). 
Table 2.3- Partial correlation of ghrelin with insulin resistance indices after 
controlling for age, Percentage of trunk fat and HDL-cholesterol 
Entire Cohort Female Male 
r p r p r p 
Glucose 0.00 0.99 0.01 0.75 -0.03 0.52 
Insulin -0.09 0.00* -0.07 0.00* -0.11 0.02* 
HOMA-IR -0.08 0.00* -0.06 0.01 * -0.10 0.02* 
HOMA-f3 -0.10 0.00* -0.09 0.00* -0.09 0.04* 
QUICK! 0.08 0.00* 0.06 0.01 * 0.10 0.02* 
*P value < 0.05 
Influence of menopause on the relationship between ghrelin and insulin resistance 
To explore the influence of menopause on the association between ghrelin and insulin 
resistance, females were divided into pre-menopausal and post-menopausal groups and 
partial correlation analysis was performed after controlling for age, trunk fat percentage 
and HDL-cholesterol. In pre-menopausal women, there was a significant negative 
relationship between circulating ghrelin level and insulin, HOMA-IR, HOMA-f3 and 
positive correlation between circulating ghrelin and QUICKI whereas in post-menopausal 
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women, there were no significant associations between ghrelin and insulin resistance 
factors (Table 2.4). 
Table 2.4- Partial cor relation analyses of ghrelin with physical and 
biochemical characteristics regarding menopausal status 
pre-menopausal post-menopausal 
women women 
r p r p 
Glucose (mmol/1) 0.00 0.98 0.01 0.81 
Insulin (pmol/L) -0.08 0.02* -0.06 0.14 
HOMA-IR -0.07 0.03* -0.05 0.25 
HOMA-B -0.09 0.01 * -0.07 0.08 
QUICK! 0.07 0.04* 0.05 0.26 
*P value < 0.05 
Comparison of insulin resistance in low, medium and high ghrelin groups 
After dividing volunteers into three groups based on the ghrelin tertile, general linear 
model (multivariative analysis) was used for the comparison of insulin resistance between 
low, medium and high ghrelin groups. For insulin, HOMA-IR, HOMA- f3 and QUICK! 
there was no significant difference between low and medium ghrelin level or medium and 
high ghrelin levels but significant difference was evident between low and high ghrelin 
level (p value = 0.003, 0.01, 0.00 and 0.02 respectively). Figure 2.1 shows the mean and 
95% confidence interval for mean of insulin, HOMA-IR, HOMA-(3 and QUICK! in high, 
medium and low ghrelin groups. 
Comparison of ghrelin level between diabetic and non-diabetic subjects 
Repeating the analysis after excluding the volunteers who report a history of diabetes and 
volunteers who had fasting blood glucose more than 7 mmoi/L, no significant changes in 
the results were present. 
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Association between fasting ghrelin and age and HDL-clwlesterol 
Pearson correlation analyses showed no significant relationship between circulating 
ghrelin level and body composition characteristics, either in the total cohort or in the 
males and females separately. There was a positive correlation between fasting ghrelin 
level and age in the entire cohort (r = 0.08 and p = 0.00) and in females (r = 0.12 and p = 
0.00) but not in males (r = -0.02, p = 0.72). No association was found between circulating 
ghrelin level and HDL-cholesterol. 
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Figure 2.1- Error bars show the mean and 95% confidence interval for mean of 
insulin(A), HOMA-IR (B), HOMA-J3 (C) and QUICKI (D) values in high, medium 
and low ghrelin groups 
32 
Discussion 
The major finding in the present study is that circulating fasting ghrelin level is negatively 
correlated with insulin resistance and beta cell function in our CODING study. These 
findings were consistent using both HOMA and QUICK! as indices of insulin resistance. 
More importantly, our results indicate that the association of ghrelin with insulin 
resistance and secretion is independent of age, body composition and circulating HDL 
cholesterol. To our knowledge this is the largest study to evaluate the effect of ghrelin on 
insulin resistance, with the most comprehensive controls for major confounding factors, 
in the general population. 
A number of experimental studies have evaluated the effect of ghrelin on insulin secretion 
in humans. Broglie et a!. and Tong et a/. showed that acute administration of ghrelin 
induced inhibitory effects on insulin secretion. These effects seem to be dose dependent 
and non-growth hormone mediated [12, 15]. In patients with metabolic syndrome, ghrelin 
was inversely correlated with insulin level and insulin resistance measured by HOMA-IR 
[26]. In a cross sectional study, low ghrelin level has been shown to be associated with 
type 2 diabetes and insulin resistance in middle-aged subjects and these associations 
remained significant after adjustment for sex, BMI and age [ 17]. Our findings provide 
further evidence that ghrelin level is negatively correlated with insulin level and 
resistance. 
In pancreatic P-cells, ghrelin can inhibit glucose-induced insulin release v1a Gai2-
mediated activation of voltage dependent K+ channels and diminish action potential in ~­
cells [27] . Moreover, high ghrelin level may down-regulate growth hormone or its 
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receptors and decrease insulin secretion secondarily [28]. Ghrelin receptors have been 
identified in the pancreas and ghrelin is produced partly in islet 8 cells of the pancreas. 
Therefore the inhibitory effect of ghrelin on pancreatic (3-cells might partly be due to 
paracrine mechanisms [15, 29]. Lower insulin resistance might be a compensatory 
response to decreased insulin level to maintain blood glucose within a normal range. 
In contrast, there are some studies that did not report any association between ghrelin 
level and insulin resistance. A group in Sweden did not observe association between 
ghrelin level and insulin sensitivity measured by euglycemic hyperinsulinemic clamp in 
104 subjects after adjustment for fat free mass [19]. Measurement of insulin resistance 
with euglycemic hyperinsulinemic clamp was certainly good. However, the sample size 
was very small compared with our sample size. On top of that the older age in this study 
could hinder the detecting of signals because of increased use of medications and other 
common chronic diseases. In a longitudinal study with 5.1 year follow up on 201 
subjects, glucose tolerance and baseline fasting ghrelin level were measured. They found 
that fasting ghrelin levels failed to predict the development of glucose intolerance or type 
2 diabetes [20]. The major concern for this study is that ghrelin is only one of the many 
factors affecting the development of insulin resistance and type 2 diabetes, so the possible 
effect of ghrelin on insulin resistance cannot be excluded. 
Furthermore, there are studies that found a positive association between ghrelin level and 
insulin resistance. Vestegard et al. reported increased insulin resistance in 6 healthy men 
and eight hypopituitary men on stable replacement therapy with growth hormone and 
hydrocortisone after acute administration of ghrelin [16] . Similarly, acute administration 
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of ghrelin in 10 patients who had the total gasterectomy and truncal vagotomy, reduced 
insulin mediated glucose disposal rate [30]. Due to the small sample size the results of 
these studies were only suggestive. 
Our results, together with the results from others, indicate that there is a very wide range 
of ghrelin concentration in the population. The large standard deviation of circulating 
ghrelin would require a very large sample size to achieve the statistical power to detect 
the effect of ghrelin on insulin resistance and other phenotypes. This factor has to be 
considered since most of the previous studies seemed to be under power because of the 
small sample size which could lead to false positive or false negative results. 
As the only known orexigenic gut hormone, the role of ghrelin in the development of 
human obesity is still unclear. Data from animal studies indicate that ghrelin induces the 
accumu lation of adipose tissue [31 ]. However, cross sectional studies in humans reported 
negative correlation between ghrelin and adiposity [32]. In our current study we did not 
find significant association between fasting ghrelin levels and any adiposity phenotype. 
Detailed information will be available in another paper from our laboratory. 
Effect of age on circulating ghrelin is still unclear. Paik and Thoshinai reported an inverse 
correlation between ghrelin and age [33, 34] whereas Cummings et al. reported a positive 
correlation between ghrelin level and age and they suggest that rising ghrelin levels 
could play a role in the effect of aging on increasing body fat [35]. In the present 
CODING study a positive correlation was observed between circulating ghrelin and age. 
As indicated in the analysis, the effect of age on ghrelin has been properly controlled in 
the present study. 
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In postmenopausal women, insulin resistance increases likely due to the reduced levels of 
sex hormones and physical activity and increased body fat [36-38]. Several studies 
explored the effect of menopause on ghrelin level. Purnell et al. reported that menopausal 
status or hormone replacement therapy do not have any effect on the ghrelin levels [39]; 
while Soni et al. found that estrogen hormone therapy can decrease ghrelin level and 
discontinuing it can increase ghrelin level in post-menopausal women [40]. In our study 
we did not see any significant difference in ghrelin level between premenopausal and 
postmenopausal women. However, we found a significant association between ghrelin 
and insulin resistance only in premenopausal women and not in postmenopausal women. 
The factors involved in the absence of relationship between circulating ghrelin and insulin 
sensitivity in postmenopausal women could be complicated by many factors including 
reduced level of sex hormones and possibly use of medications. 
Previous studies have reported that ghrelin can bind to HDL particles in the blood [ 41] 
and HDL cholesterol level might have some effect on the measurement of ghrelin [39]. 
However, in our CODING study no significant association between circulating ghrelin 
and HDL-cholesterol was found. 
To control the potential effect of diabetes status on the results of our study all analyses 
were repeated after volunteers who had blood glucose more than 7 mmoi/L and reported 
to have diabetes were excluded. All findings remained significant. 
In summary, the relationship between fasting ghrelin level and insulin resistance was 
systematically evaluated in the large CODING study with more than 2000 adult subjects 
from the Newfoundland population. To our knowledge this is the largest general 
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population based study on the relationship between fasting ghrelin level and insulin 
resistance. Major confounding factors including age, gender, menopausal status and 
HDL-cholesterol level have been carefully analyzed and properly controlled. With the 
strong statistical power we provide reliable evidence that ghrelin may be a factor that help 
to reduce insulin resistance at the population level. This association is absent in the 
postmenopausal women. However, because of the nature and limitations of a cross 
sectional study, longitudinal study is warranted to fill the knowledge gap. 
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Background: Ghrelin and peptide YY (PYY) are appetite regulating hormones secreted 
from the gastrointestinal tract (gut). Aside from their known effect on energy 
homeostasis, accumulating data indicates that these gut hormones also affect bone 
metabolism. However, data regarding the influence of ghrelin and PYY on bone density 
in humans is very limited, and the results are inconclusive. This study was designed to 
investigate the potential association between circulating ghrelin and PYY with bone 
density indices in the general population. 
Methods: A total of 2257 adult subjects from the CODING (Complex Diseases in the 
Newfoundland Population: Environment and Genetics) Study participated in this 
investigation. Acylated ghrelin and total PYY were measured in fasting serum with the 
Enzyme- Linked Immunosorbent Assay (ELISA) method. Bone mineral density was 
measured by dual-energy X-ray absorptiometry at the spine, femoral neck, and total hip. 
Multiple regression analyses adjusting for age, BMI, physical activity, smoking, and 
alcohol consumption were employed to analyze the association between serum ghrelin 
and PYY with bone mineral density parameters. 
Results: Significant positive associations of ghrelin level with L2-L4 BMD, L2-L4 Z-
score, femoral neck BMD, femoral neck Z-score, total hip BMD, and total hip Z-score 
were found in women. No significant correlations between ghrelin and bone density 
indices were revealed in men. After dividing the female group into pre-menopausal and 
post-menopausal, ghrelin was positively correlated with femoral neck Z-score, and total 
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hip Z-score in pre-menopausal women and L2-L4 BMD, and Z-score in post-menopausal 
group. Moreover, no significant association was discovered between serum PYY and 
bone density at any site. 
Conclusion: Our results suggest a beneficial association of circulating ghrelin level with 
bone density in women at the population level. This association is independent of major 
confounding factors including body composition, physical activity, age, alcohol 
consumption and smoking. Effect of menopause on this association seemed to be site 
specific. However, PYY does not seem to be associated with bone density parameters. 
Key words: Ghrelin, Peptide YY, Osteoporosis, Bone Density 
Background 
Osteoporosis is a global problem. According to the International Osteoporosis Foundation 
(I OF) data, the annual treatment cost for osteoporosis fractures of people in the workplace 
in the USA, Canada and Europe is almost 48 billion USD [1]. Therefore, understanding 
the potential factors that cause osteoporosis is of great value. Most cases of osteoporosis 
are idiopathic because of estrogen deprivation and aging [2]. However, many other 
factors are involved in the pathogenesis of osteoporosis. In populations aged 50 years and 
over, secondary causes of osteoporosis such as endocrine, gastrointestinal, and connective 
tissue diseases, have been found in 41.4% of women and 51.3% of men [3]. In addition, 
the gastrointestinal hormones, ghrelin and PYY, which aid in energy homeostasis and 
weight management, have been found to be involved in the regulation of bone density. 
Ghrelin is a 28 amino acid appetite stimulant peptide secreted primarily from the 
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stomach, and PYY is an appetite suppressant hormone secreted from the enteroendocrine 
cells ofthe ileum and colon [4-6]. 
The initial investigations regarding the effect of ghrelin on bone density, that were 
conducted on rodents and in vitro situations, have shown that ghrelin increases osteoblast 
replication, osteoblast specific gene expression, differentiation of osteoblast markers, and 
bone mineral density (BMD) [7-9] . Human studies regarding the effect of ghrelin on bone 
density are very limited and the results are inconsistent. In a study w ith 137 elderly men, 
ghrelin was positively correlated with femoral neck BMD [I 0]. In another study, eleven 
months after gasterectomized surgery, a significant decrease in circulating ghrelin and 
bone mineral density was found [ll]. However, no association was found between serum 
ghrelin concentration with femoral neck BMD or lumbar spine BMD in 81 Korean men 
[12]. A study by Makovey et a!. also did not find any significant correlation between 
ghrelin concentration and bone mass parameters in 79 pairs of opposite sex twins [13]. 
Similarly, Weiss et a!. did not find any association between ghrelin and BMD in older 
men or women after adjusting for age and BMI [14]. 
Results from animal studies on the effect of PYY on bone density are also inconsistent. 
The hypothalamic Y2 receptor serves as the receptor of PYY. Y2 receptor deficient mice 
have increased trabecular bone volume, and rate of bone mineralization and formation 
[ 15] . However, PYY deficient mice developed decrease of trabecular bone mass and 
osteopenia [16] . Human studies on the effect of PYY on bone density are extremely 
limited in terms of a general population level, as previous studies have only been 
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performed on special groups such as anorexic patients or women experiencing exercise 
[17-20). 
Emerging data suggest the functionally related gut hormones, ghrelin and PYY, are linked 
to bone metabolism and BMD. However, data from humans is limited and the results are 
contradictory and subject to statistical errors due to small sample size. Moreover, BMD is 
a complex physiological measure and many factors can exert a significant effect on it. 
Therefore, it is important to evaluate whether the possible associations between these two 
important gut hormones and bone mineral density are independent of major confounding 
factors. The objectives of the current study were: 1) to determine if ghrelin and PYY are 
associated with bone density parameters in a large population-based cohort; 2) to evaluate 
whether this possible association is different in men and women, and also in pre- and 
post-menopausal women; and 3) to explore whether the possible associations between 
ghrelin or PYY and bone mineral density are independent of age, BMI, physical activity, 
alcohol consumption, and smoking. 
Methods 
Study population 
A total of 2,257 subjects from the CODING (Complex Diseases in the Newfoundland 
population: Environment and Genetics) study, including 551 men and 1706 women were 
recruited in the present study through advertisement in public media and word of mouth 
by previous volunteers. All volunteers were at least third-generation Newfoundlander, 
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between the ages of 20 and 79 years old, without any serious metabolic, cardiovascular, 
or endocrine diseases, and women were not pregnant at the time of the study. 
Ethical considerations 
This study was approved by the Health Research Ethics Authority of the Faculty of 
Medicine of Memorial University, St. John' s, Newfoundland, Canada. Informed assent 
and consent were obtained from all of the volunteers. 
Anthropometric and body composition measurements 
Anthropometric measurements were performed with participants dressed in a 
standardized hospital gown. Standing height was measured to the nearest 0.1 em using a 
fixed stadiometer. Subjects were weighed to the nearest 0.1 kg using a platform manual 
scale balance (Health 0 Meter, Bridgeview, IL). BMI was calculated from weight and 
height in kilograms per square meter [(weight-kg) I (height-m)2) . 
Body composition and bone mineral density measurements 
The measurements of bone mineral mass were carried out by dual-energy X-ray 
absorptiometry (DXA) Lunar Prodigy (GE Medical Systems, Madison, WI) equipped 
with encore software vl2.3 . Volunteers were scanned by the same technician in 
standardized clothing (hospital gown) with no removable metal objects, while lying flat 
on their backs with arms at their sides. In all subjects, BMD was measured at the sites of 
lumbar spine, femoral neck, and total hip. Moreover, Z-score and T-score were measured 
for these areas. 
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According to the World Health Organization (WHO), T-score ~ -1 is considered normal, 
T-score < -1 and > -2.5 is considered osteopenia, and T-score :s; -2.5 is considered 
osteoporosis [21] . 
Physical activity 
The Baecke questionnaire was used for evaluation of the subject' s physical activity based 
on the work, sports, and leisure activity [22]. 
Blood analysis 
Venous blood samples were obtained from all volunteers in the morning after an 
overnight fast (12 hours). Serum samples were isolated from blood and stored at -80 oc 
until assayed. 
Serum acylated ghrelin was measured with an Enzyme - Linked Immunosorbent Assay 
(ELISA) method (Human Acylated Ghrelin Enzyme Immunoassay Kit of Spibio-bertin 
pharma). All samples used for the measurement of acylated ghrelin were thawed for the 
first time on the day of analysis, and while running ELSIA kits, all work was completed 
on tee. Intra- and inter-assay coefficients of variation (CV) were 5.7% and 17% 
respectively. 
Serum total PYY concentration was measured with the ELISA kit from Millipore 
(Millipore Corporation Pharamaceuticals, Billerica, MA, USA). The intra-assay CV was 
4.8 % - 5.4% and inter-assay CV was 5.1 % [23]. 
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Statistical analysis 
Statistical analyses were performed using SPSS, version 20.0 (SPSS Inc, Chicago). All 
tests were two-sided and p value < 0.05 was considered to be statistically significant. 
Evaluation of data normality was performed with the Kolmograv- Smimov test. 
Demographic and physical characteristics values were expressed as mean (standard 
deviation). Logarithmic transformation was performed for ghrelin, PYY and bone density 
parameters, except Z-score (because of the negative values) that were not normally 
distributed. These values were reported as median, minimum and maximum in the results. 
Analyses were performed on the entire cohort and, as well, on men and women 
separately. Women were further subdivided according to their menopausal status and the 
analyses were conducted between pre- and post-menopausal groups. Pearson correlation 
was used to determine the relationship between ghrelin and PYY and bone mineral 
density indices. Stepwise multiple regression analyses were used to identify predictors of 
bone density indices. Gut hormones and other identified confounders of bone density 
such as age, BMI, physical activity, smoking, and alcohol consumption, were considered 
independent variables. Percentage of body fat as the more accurate measure for body 
composition was also replaced with BMI to see whether the effect of body fat percentage 
differed from BMI. The results were similar. Therefore, in order to remain consistent with 




Mean and standard deviation of demographic and physical characteristics of the subjects 
are presented in Table 3 .1. Ghrelin, PYY, and bone density parameters are described as 
median, minimum and maximum in Table 3.2. According to the WHO criteria (based on 
the L2-L4 T-score), 80.8% of volunteers had normal bone density, 16.9% were 
osteopenic, and 2.2 % were osteoporotic. According to the femoral neck T -score, 76.6% 
were normal, 22.6% and 0.7% met the criteria of osteopenia and osteoporosis 
respectively, and based on total hip T-score 83.5%, 16.2%, and 0.3% were normal, 
osteopenic, and osteoporotic respectively. 





Percent body fat (%) 
Percent trunk fat (%) 
Percent android fat (%) 
Percent gynoid fat(%) 
Total fat mass (kg) 
Total lean mass (kg) 
Entire cohort Female Male 
(n = 2257) (n = 1706) (n = 551) 
Mean (SD) Mean (SD) Mean (SD) 
43.1 (12.3) 44 (11.7) 40.3 (13.7) 
73.4 (15.8) 69.5 (14.1) 85.4 (14.7) 
165.6 (8.5) 162.3 (5 .9) 176.1 (6.5) 
26.7 (5.1) 26.4 (5.2) 27.5 (4.5) 
34.5 (9.4) 37.5 (7.6) 25. 1 (7.8) 
36.6 (9.7) 38.8 (8.8) 30 (9.3) 
41.9 (11.3) 43.7 (10.6) 36.1 (11.4) 
40.8 (9.8) 44.7 (6.6) 28.6 (8) 
25.5 (10.3) 26.6 (10.2) 22. 1 (9.8) 
44.6 (10.6) 39.7 (53.9) 59.9 (7.9) 
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Pearson correlation of ghrelin and PYY with bone density measures 
Pearson correlation analyses showed positive correlations between ghrelin and L2-L4 Z-
score, femoral neck Z-score, and total hip Z-score in the entire cohort (r = 0.05, p = 0.03, 
r = 0.07, p = 0.004, and r = 0.05, p = 0.03 respectively), and in females (r = 0.08, p = 
0.006, r = 0.09, p = 0.003 , and r = 0.07, p = 0.006 respectively). 
For PYY, there was no significant association with any of the bone density parameters 
either in the entire cohort or in the males and females separately. 
Multiple regression analyses of ghrelin and PYY with bone density indices adjusting for 
BMI, age, physical activity, smoking and alcohol consumption 
Stepwise multiple regression analyses were performed to clarify the determinants of 
BMD and Z-score in males and females separately. In females, there were significant 
positive associations between ghrelin and L2-L4 BMD and Z-score, femoral neck BMD 
and Z-score, and total hip BMD and Z-score (Table 3.3). [For Z-score, age was not 
included in the model because Z-score is the number of standard deviations above or 
below what is normally expected for someone of their age, sex, and ethnic or racial 
origin] 
For PYY after entering the variables into the model, no significant association was found 
between PYY and BMD or Z-score values. 
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Table 3.2- Descriptive statistics for ghrelin, PYY, and bone density indices 
Variables Entire Cohort Female Male 
Median Min-Max Median Min-Max Median Min-Max 
Ghrelin (pg/ml) 194.7 0.74- 2329.09 193.44 0.74-2329.09 196.73 2.12-2289.26 
PYY (pg/ml) 95 3.67- 368.53 92.52 3.67-368.53 103.67 8.37-364.66 
Spine BMD (g/cm2) 1.21 0.76- 1.85 1.20 0.76- 1.85 1.26 0.81-1.78 
Left Hip BMD (g/cm2) 0.98 0.52-1.83 0.96 0.52- 1.65 1.04 0.67- 1.83 
Total hip BMD (g/cm2) 1.02 0.61- 1.68 0.99 0.61- 1.58 1.1 0.76- 1.68 
L2-L4 Z score(%) 0.2 -4.1- 6.1 0.2 -4.1-6.1 0.1 -3.4- 4.8 
Femur Neck Z score (%) 0.1 -2.5- 5.7 0.2 -2.5- 5 0.1 -2- 5.7 
Total hip Z-score {%} 0.2 -3.12-4.4 0.21 -3 .12-4.12 0.1 8 -2.63- 4.4 
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Table 3.3- Regression anal~ses of ghrelin with BMD and Z-scores in women and men 1 
Female Male 
Variables lr (95% C!)t p R2 Variables ~ {95% C!) p R2 
L2-L4 BMD Age -0.003 (-0.003, -0.002) <0.001 0.1 BMI 0.006 (0.003, 0.009) <0.00 1 0.045 
BMI 0.005 (0.004, 0.007) <0.001 Age -0.00 1 (-0.002, 0.000) 0.0 12 
Smoking -0.043 (-0.065, -0.02 1) <0.001 
Ghrelin 0 .009 (0.002, 0.0 17) 0.015 
Femoral Neck BMD Age -0.004 (-0.005, -0.004) <0.001 0.238 Age -.006 (-0.006, -0.005) <0.00 1 0.361 
BMI 0.008 (0.006, 0.009) <0.001 BMI .012 (0.0 10, 0.0 15) <0.00 1 
PA 2 0.011 (0.007, 0.0 16) <0.00 1 PA .015 (0.007, 0.023) <0.001 
Smoking -0.044 (-0.065, -0.023) <0.001 Smoking -.047 (-0.083, -0.0 I 0) 0.012 
Ghrelin 0.008 {0.000, 0.015) 0.04 Alcohol .00 1 (0.000, 0.002) 0.020 
Total Hip BMD BMI 0.011 (0.009, 0.0 12) <0.00 1 0.234 BMI .013 (0.011 , 0.0 16) <0.001 0.247 
Age -0.003 ( -0.003, -0.002) <0.00 1 Age -.002 (-0.003, -0.00 1) <0.001 
PA 0.009 (0.005, 0.0 14) <0.001 PA .013 (0.005, 0.020) 0.002 
Smoking -0 .036 (-0.057, -0.0 16) <0.001 Alcohol .00 1 (0.000, 0.002) 0.019 
Ghrelin 0.009 {0.002, 0.0 1 6~ 0.009 Smoking -.037 ( -0.072, -0.002) 0.036 
L2-L4 Z-score Smoking -0.458 ( -0.675, -0.24 1) <0.001 0.022 
Ghrelin 0 . 102 (0.027, 0.177~ 0.007 
Femoral Neck Z-score Smoking -0.338 (-0.502, -0.1 73) <0.001 0.04 PA 0.1 58 (0.092, 0.224) <0.00 1 0.085 
PA 0.078 (0.044, 0. 11 3) <0.001 BMI 0.055 (0.031 ' 0.079) <0.001 
Ghrelin 0 .073 (0.015, 0.131) 0.0 13 
BMJ 0.013 (0.003, 0.024~ 0.0 15 
Total Hip Z-score BMJ 0.043 (0.033, 0.053) <0.001 0.076 BMI 0.08 (0.058, 0.1 02) <0.001 0.137 
Smoking -0.286 (-0.447, -0.125) 0.001 PA 0.122 (0.059, 0.185) <0.00 1 
PA 0.059 (0.026, 0.093) 0.001 Alcohol 0.007 (0.000, 0.015) 0.042 
Ghrelin 0.081 (0.024, 0. 1 37~ 0.005 
1Regression model adjusted for age, BMI, alcohol consumption, physical activity, and smoking 2 Physical Activity · Unstandardized p coefficients t95% 
Confidence Interval 
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Influence of menopause on the relationship between ghrelin and bone density 
To evaluate the influence of menopause on the association between ghrelin and bone 
density, multiple regression analyses were performed in females after they were divided 
into pre- and post-menopausal groups. Significant associations were seen between ghrelin 
and femoral neck and total hip Z-scores in pre-menopausal women. In post-menopausal 
group ghrelin was positively associated with L2-L4 BMD, and Z-score (Table 3.4). 
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Table 3.4- Regression anal~ses of ghrelin with BMD and Z-scores in women based on meno(!ausal status 1 
Pre-menol!ausal (N= 971) Post-menol!ausal (N= 653) 
Variables ~ · (95% C!)t p R2 Variables ~ (95% CI) p R2 
L2-L4 BMD BMl 0.005 (0.003, 0.006) <0.001 0.05 BMI 0.006 (0.003, 0.008) <0.00 1 0.088 
Smoking -0.032 (-0.059, -0.004) 0.023 Smoking -0.055 ( -0.092, -0.0 17) 0.005 
Age -0.002 ( -0.004, -0.00 I) 0.00 1 
Ghrelin 0.014 (0.00 I, 0.027) 0.037 
Femoral Neck BMD BMI 0.008 (0.006, 0.010) <0.001 0.139 Age -0.004 ( -0.006, -0.003) <0.00 1 0.195 
Age -0.003 ( -0.004, -0.002) <0.001 BMJ 0.007 (0.005, 0.009) <0.00 1 
PA 2 0.013 (0.007, 0.0 19) <0.001 Smoking -0.044 (-0.077, -0.012) .007 
Smoking -0.039 (-0.067, -0.010) 0.007 PA 0.008 (0.001, 0.015) .019 
Total Hip BMD BMI 0.01 (0.008, 0.0 I I) <0.001 0. 164 BMI 0.0 11 (0.009, 0.0 13) <0.00 1 0.263 
PA 0.014 (0.008, 0.0 19) <0.001 Age -0.003 (-0.004, -0.002) <0.001 
Smoking -0.034 (-0.063, -0.006) 0.017 Smoking -0.04 1 (-0.071, -0.01 I) 0.008 
L2-L4 Z-score Smoking -0.394 (-0.673, -0.1 I 6) 0.006 0.01 2 Smoking -0.596 (-0.964, -0.229) 0.002 0.034 
Ghrelin 0.135 (0.006, 0.263) 0.04 
Femoral Neck Z-score PA 0.106 (0.058, 0. 154) <0.001 0.051 Smoking -0.42 1 (-0.658, -0. I 85) .001 0.025 
Smoking -0.304 (-0.538, -0.071) 0.01 I 
BMI 0.018 (0.003, 0.033) 0.018 
Ghrelin 0.096 (0.01 7, 0. 175) 0.018 
Total Hip Z-score BMI 0.043 (0.028, 0.058) <0.001 0.083 BMJ 0.043 (0.029, 0.057) <0.00 1 0.084 
PA 0.092 (0.044, 0.140) <0.001 Smoking -0.32 ( -0.552, -0.089) 0.007 
Smoking -0.315 (-0.546, -0.085) 0.007 
Ghrelin 0.107 (0.029, 0. 185) 0.008 




In the present study, we examined the associations between the levels of circulating 
ghrelin and PYY, with bone mineral density indices controlling for major confounding 
factors in the Newfoundland population. The most important finding from our study is 
that circulating fasting ghrelin level is significantly and positively correlated with femoral 
neck, total hip, and lumbar spine bone mineral densities and Z-scores in females. More 
importantly, we demonstrated that the association of ghrelin with bone mineral density is 
independent of age, body composition, alcohol consumption, physical activity, and 
smoking. We found out that serum PYY is not significantly correlated with any of the 
bone density measures in this study. To our knowledge this is the largest human study 
that simultaneously evaluated the relationship of the two gut hormones, ghrelin and PYY, 
with bone mineral density with comprehensive control of major confounding factors . 
Similarly, a study with the sample size of 137 men aged 55 years or older revealed a 
positive correlation between ghrelin and femoral neck BMD [ 1 0] . The average ages in 
both women and men in our study are younger, and the results are very reliable with such 
a large sample size. 
Data from both cultured cell based and animal experiments supported the significant 
association between ghrelin and BMD. An animal study has shown that ghrelin receptors 
are present in osteoblasts and ghrelin can increase osteoblast proliferation and 
differentiation markers [9]. Moreover, gasterectomy in mice, in which ghrelin secretion is 
significantly reduced, can cause decreased bone density [24] . 
The mechanism by which ghrelin increases bone mineral density has yet to be completely 
understood. Ghrelin is a natural ligand for the growth hormone secretagogue receptor, and 
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growth hormone increases bone density. Therefore, ghrelin may also affect bone density 
through the growth hormone related pathway. Moreover, previous studies have shown 
that osteoblasts express the ghrelin receptor. Ghrelin stimulates both osteoblast cell 
proliferation and differentiation [9]. However, Delhanty eta!. did not find expression of 
GHS-Rla (Growth hormone secretagogue Receptor-la) in osteoblasts. They found out 
that the effect of ghrelin on bone density is through ERK and PBK, and MAPK pathway 
[25]. A recent study on wild type and ghrelin receptor deficient mice has shown that 
ghrelin can inhibit osteoclastogenesis and this effect is age dependent. With aging 
inhibitory effect of ghrelin on osteoclasts increases [26]. 
Data from some studies do not support the association between ghrelin and bone density. 
In ghrelin knockout mice, bone mineral density and bone mineral content between ghrelin 
-1- mice and wild type mice were similar [27]. There was no significant association 
between ghrelin and BMD in a study consisting of 80 male adults. In this study, the effect 
of alcohol, smoking, and physical activity was not controlled [12]. Also, in a study with 
977 old adults, no significant association was found between ghrelin and BMD in either 
sex after controlling for age and BMI [14]. Ghrelin has extremely high standard 
deviation, and therefore studies on ghrelin need a very large sample size to have 
reasonable statistical power. Otherwise it is likely to have type II error. Caution should be 
taken on either negative or positive results from the studies with small sample size. 
In our study, the positive association between ghrelin and BMD was found only m 
females. The reason for the sex difference in the association between ghrelin and BMD is 
unknown, and could be due to the small number of male subjects, differences in sex 
hormones, or other unknown factors. 
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Bone density is a complex physiological marker. Many factors can potentially be 
involved in the regulation ofBMD. In the present study, one of the important goals was to 
clarify if the significant positive association of ghrelin with bone mineral density is 
secondary to any confounding factor. We were able to demonstrate that the positive 
association is indeed independent of the major confounding factors available in the study. 
Physical activity and age are important in determining bone density [28, 29]. In our study, 
ghrelin was positively correlated with age. Previous primary studies have shown that 
bone density decreases at most sites after age of fifty due to trabecularization of cortical 
bones [30, 31]. Physical activity, especially weight-bearing sport-specific activity, is 
positively associated with femoral neck bone density after adjustment for age, sex, 
ethnicity, smoking, menopausal status, lean body mass, and total body fat [32]. After 
adjusting for age and physical activity, the association of ghrelin with bone density 
indices remained significant. 
Alcohol consumption in adolescence can also cause reduction in bone density [33]. In our 
study, almost 77% of the volunteers reported the drink of alcohol (irrespective of the 
dosage of the alcohol they drink). Therefore alcohol drinking was adjusted in the analyses 
as well, and it did not affect the significant results. 
Previous studies on the effect of menopause on ghrelin are contradictory. In a study on 57 
females, the level of ghrelin was lower in peri-menopausal and post-menopausal women 
compared to pre-menopausal group, and ghrelin seemed to be positively correlated with 
bone density [34]. However, another study did not reveal any difference between ghrelin 
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levels of pre- and post-menopausal women [35]. To eliminate the potential influence of 
menopausal status, the females were divided into two groups based on the menopausal 
status. We found positive associations between ghrelin and femoral neck, and total hip Z-
scores in pre-menopausal women. In post-menopausal group, ghrelin was associated 
positively with L2-L4 BMD and Z-score. Although this difference might be consequence 
of changes in sex hormones caused by menopause, factors such as physical activity, body 
composition, and the smaller number of women in post-menopausal group might also be 
the reason for the difference observed between these groups. 
In this study, fasting PYY was not significantly associated with bone density in the entire 
cohort or in males or females. Previous studies evaluated the association between PYY 
and bone density in metabolic diseases that affect PYY such as anorexia nervosa or in 
special groups such as athletes with high physical activity. In two studies on anorexia 
nervosa patients, PYY was negatively associated with bone density [19, 36]. However, 
these studies were done in patients that had lower body weight and usually lower BMD 
because of the anorexia nervosa [3 7]. Considering many important factors including 
smoking, alcohol consumption, and physical activity, it would be difficult to interpret the 
effect ofPYY on bone density in this special group and in small study. 
In another study on 4 7 adolescent girls (aged 12-18 years) in 3 groups of amenorrheic 
athletes, eumenorrheic athletes, and non-athletic controls, PYY was a negative predictor 
of lumbar Z-score. In their study, although they controlled for lean mass, other 
confounding factors such as physical activity, alcohol consumption, smoking were not 
entered in the regression model [20]. The subjects of this study were only adolescents. 
55 
The amount of physical activity and also age may exert significant influence on BMD and 
appetite, which in turn could affect PYY. 
We did not find any significant association between PYY and bone density indices. Our 
data suggest that PYY is not likely an important player in determining BMD. The effect 
of PYY on bone density, that was reported in previous studies, might be through Y2 
receptors to reduce NPY [15]. Also, effect ofPYY on bone density might be secondary to 
its effects on body composition and BMI. 
Our study had certain limitations. We had a cross-sectional study and correlation data 
collected does not prove causality. Therefore, interventional study of ghrelin 
administration to osteoporotic patients might be necessary to further evaluate this finding. 
Also, vitamin D and bone density markers were not measured in our study. Another 
limitation of our study was that the random design of the study evidently resulted in the 
recruitment of volunteers, where the number of males was less than females. Despite 
these limitations we are confident that considering the effect of two important gut 
hormones simultaneously with controlling most of the confounding factors in a big 
population base study made our results unique and reliable. 
Conclusions 
The present study investigated the relationship of two gut hormones, ghrelin and PYY, 
with BMD in the Newfoundland population. To our knowledge, this is the first study that 
simultaneously investigates the association of ghrelin and PYY with BMD. It is also the 
largest population based study with the most number of confounding factors adjusted in 
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analysis. With such a large sample size, the present study had significantly higher power 
than all reported studies to detect the potential statistical signals. The significant positive 
associations of circulating ghrelin with BMD in women suggest that high levels of ghrelin 
might have beneficial effects on bone density in the female population. The beneficial 
effect is independent of body composition, physical activity, age, and smoking. The 
clinical significance of ghrelin on BMD warranted future studies. In our study, PYY was 
not a significant player in determining bone density. 
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Diabetes and osteoporosis are common endocrine disorders with high global burden [ l , 
2]. Exact mechanisms for developing both diseases are unknown. Interaction of genetics, 
endocrine, and environmental factors affect both glucose homeostasis and bone density 
measures [3-5]. Most recently, data mainly from animal models have suggested that gut 
hormones, especially ghrelin and PYY, may have a role in bone density and glucose 
homeostasis [6-9]. Ghrelin is an orexigenic gut hormone released from gastric fundus. 
Since its initial discovery as a growth hormone secretagogue receptor, ghrelin has been 
shown to be involved in different functions such as regulation of food intake and energy 
homeostasis [10]. However, the role of ghrelin on the regulation of insulin resistance and 
bone density is still unclear in humans. Very few cross-sectional studies were performed 
in this area. None of them have reasonable sample size, and results from the literature are 
controversial [ ll-14]. Furthermore, previous investigations have not adequately 
controlled for confounding factors that might cause the association between ghrelin and 
insulin resistance or bone density. 
Peptide YY (PYY) is another gut hormone with an anorexigenic effect, secreted from 
enteroendocrine L-cells of the distal part of gastrointestinal tract [ 15]. PYY mostly acts 
through Y2 receptor [16]. Separate studies on Y2 receptor knockout mice and PYY 
knockout mice revealed that PYY is also involved in the regulation of bone metabolism 
[9, 17]. However, there is a necessity to explore the association between PYY and bone 
density in a large population based study. 
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Therefore, the objectives of this project were: 1) To investigate the association between 
circulating fasting ghrelin and insulin resistance adjusting for age, gender, percentage of 
body fat, and HDL- cholesterol in the general population of the Canadian province of 
Newfoundland and Labrador. 2) To examine the effect of fasting circulating ghrelin and 
PYY on bone density in the general population, taking into consideration age, BMI, 
physical activity, smoking, and alcohol consumption as the most important confounding 
factors for bone density. 
In order to address the first objective, 2082 subjects from the Complex Diseases in the 
Newfoundland population: Environment and Genetics (CODING) study were recruited in 
our investigation. Serum ghrelin was measured with the ELISA Kit of Spibio-bertin 
pharma. Serum insulin was measured with the Immulite Immunoassay analyzer. Insulin 
resistance was determined with the homeostasis model assessment of insulin resistance, ~ 
cell function (HOMA-IR, HOMA-~), and quantitative insulin sensitivity check index 
(QUICK!). Dual-energy X-ray absorptiometry (DXA) was used for the body composition 
and bone mineral density measurements. 
Associations between circulating fasting ghrelin and insulin level, as well as insulin 
resistance indices, were evaluated with partial correlation analyses adjusting for age, 
percentage of trunk fat, and HDL-cholesterol. These analyses revealed a negative 
correlation between ghrelin and insulin resistance indices. The negative effect was not 
gender specific. Most importantly, this relationship was independent of major 
confounding factors. 
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To further explore this unique finding, we stratified our female subjects into pre-
menopausal and post- menopausal groups to determine whether menopausal status can 
affect this association. Interestingly, ghrelin was negatively correlated with insulin 
resistance only in the pre-menopausal group. These findings suggest that in post-
menopausal women other factors such as reduction in sex hormones, increase in body fat, 
decrease in physical activity, and possible use of medications are more important in 
determining insulin resistance. 
To our knowledge, this is the largest general population based study of its kind with the 
most comprehensive control of major confounding factors in the analyses. Our results, 
with a strong statistical power, suggest that ghrelin can attenuate insulin resistance. 
For the second objective, data from 2257 volunteers from the CODING study were used. 
DXA scan was performed for measurement of bone density at the spine, femoral neck, 
and total hip. Stepwise multiple regression analyses adjusting for age, BMI, physical 
activity, smoking, and alcohol consumption were employed to explore the relationship 
between ghrelin and bone mineral density parameters. 
Significant positive associations were revealed between ghrelin level and L2-L4 BMD, 
L2-L4 Z-score, femoral neck BMD, femoral neck Z-score, total hip BMD, and total hip 
Z-score in women. After stratifying the female group to pre-menopausal and post-
menopausal, the favorable association was significant for femoral neck and total hip Z-
scores in pre-menopausal group, and L2-L4 BMD and Z-score in post-menopausal group. 
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Circulating PYY was not significantly associated with bone density either in entire cohort 
or in men and women separately. 
Our results indicate that ghrelin has beneficial effect on femoral and lumbar spine bone 
mineral densities and Z-scores in females. Additionally, we demonstrated that this 
protective effect is independent of age, body composition, alcohol consumption, physical 
activity, and smoking. 
It is important to identify our limitations in this project. We performed an observational 
study and correlation data collected do not prove causality. In order to get a better 
understanding of the effect of ghrelin on insulin resistance or bone metabolism, 
longitudinal studies or interventional studies of ghrelin administration in diabetic or 
osteoporotic patients are necessary. Another limitation of this project is that there are over 
20 gut hormones, but we selected only ghrelin and PYY. Therefore, future studies on the 
role of other gut hormones and interaction between different hormones are warranted. 
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